Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. More Details
Excellent balance sheet established dividend payer.
Share Price & News
How has Glenmark Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GLENMARK is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: GLENMARK's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: GLENMARK exceeded the Indian Pharmaceuticals industry which returned 42.5% over the past year.
Return vs Market: GLENMARK matched the Indian Market which returned 53% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Glenmark Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StShould Glenmark Pharmaceuticals (NSE:GLENMARK) Be Disappointed With Their 60% Profit?
3 weeks ago | Simply Wall StEstimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
1 month ago | Simply Wall StGlenn Saldanha Is The Chairman of Glenmark Pharmaceuticals Limited (NSE:GLENMARK) And Just Spent ₹5.0m On Shares
Is Glenmark Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: GLENMARK (₹649.9) is trading above our estimate of fair value (₹580.09)
Significantly Below Fair Value: GLENMARK is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: GLENMARK is good value based on its PE Ratio (18.9x) compared to the Indian Pharmaceuticals industry average (26x).
PE vs Market: GLENMARK is good value based on its PE Ratio (18.9x) compared to the Indian market (23.8x).
Price to Earnings Growth Ratio
PEG Ratio: GLENMARK is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: GLENMARK is good value based on its PB Ratio (2.6x) compared to the IN Pharmaceuticals industry average (3.4x).
How is Glenmark Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GLENMARK's forecast earnings growth (9.4% per year) is above the savings rate (6.8%).
Earnings vs Market: GLENMARK's earnings (9.4% per year) are forecast to grow slower than the Indian market (21.2% per year).
High Growth Earnings: GLENMARK's earnings are forecast to grow, but not significantly.
Revenue vs Market: GLENMARK's revenue (8.6% per year) is forecast to grow slower than the Indian market (12.6% per year).
High Growth Revenue: GLENMARK's revenue (8.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GLENMARK's Return on Equity is forecast to be low in 3 years time (13.8%).
How has Glenmark Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GLENMARK has high quality earnings.
Growing Profit Margin: GLENMARK's current net profit margins (8.9%) are higher than last year (7.3%).
Past Earnings Growth Analysis
Earnings Trend: GLENMARK's earnings have grown by 1.3% per year over the past 5 years.
Accelerating Growth: GLENMARK's earnings growth over the past year (25%) exceeds its 5-year average (1.3% per year).
Earnings vs Industry: GLENMARK earnings growth over the past year (25%) underperformed the Pharmaceuticals industry 58.3%.
Return on Equity
High ROE: GLENMARK's Return on Equity (13.7%) is considered low.
How is Glenmark Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: GLENMARK's short term assets (₹73.6B) exceed its short term liabilities (₹42.0B).
Long Term Liabilities: GLENMARK's short term assets (₹73.6B) exceed its long term liabilities (₹43.4B).
Debt to Equity History and Analysis
Debt Level: GLENMARK's debt to equity ratio (57.8%) is considered high.
Reducing Debt: GLENMARK's debt to equity ratio has reduced from 93.4% to 57.8% over the past 5 years.
Debt Coverage: GLENMARK's debt is well covered by operating cash flow (27.7%).
Interest Coverage: GLENMARK's interest payments on its debt are well covered by EBIT (4.6x coverage).
What is Glenmark Pharmaceuticals's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: GLENMARK's dividend (0.38%) is higher than the bottom 25% of dividend payers in the Indian market (0.36%).
High Dividend: GLENMARK's dividend (0.38%) is low compared to the top 25% of dividend payers in the Indian market (1.44%).
Stability and Growth of Payments
Stable Dividend: GLENMARK's dividends per share have been stable in the past 10 years.
Growing Dividend: GLENMARK's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (7.3%), GLENMARK's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: GLENMARK's dividends in 3 years are forecast to be thoroughly covered by earnings (6.6% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Glenn Saldanha (51 yo)
Mr. Glenn Mario Saldanha has been the Managing Director and Chief Executive Officer of Glenmark Pharmaceuticals Limited since 2000. Mr. Saldanha serves as the Chief Executive Officer of Glenmark Pharmaceut...
CEO Compensation Analysis
Compensation vs Market: Glenn's total compensation ($USD1.64M) is above average for companies of similar size in the Indian market ($USD620.84K).
Compensation vs Earnings: Glenn's compensation has been consistent with company performance over the past year.
Experienced Management: GLENMARK's management team is considered experienced (3.7 years average tenure).
Experienced Board: GLENMARK's board of directors are seasoned and experienced ( 10.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: GLENMARK insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Glenmark Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources
- Name: Glenmark Pharmaceuticals Limited
- Ticker: GLENMARK
- Exchange: NSEI
- Founded: 1977
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹183.381b
- Shares outstanding: 282.17m
- Website: https://www.glenmarkpharma.com
Number of Employees
- Glenmark Pharmaceuticals Limited
- Glenmark House
- B.D. Sawant Marg
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The compan...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/23 17:26|
|End of Day Share Price||2021/07/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.